Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VISTA/VSIR drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VISTA/VSIR ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. |
View VISTA/VSIR Products |
| Gene Delivery | VISTA/VSIR ORF/Lentivirus Full-length ORF for stable cell lines. High titer (>10^8 TU/mL). |
View VISTA/VSIR Products |
| Benchmark Ab | Anti-VISTA (Sequence of JNJ-61610588) Recombinant positive control, IgG1 format. |
View VISTA/VSIR Products |
| Validator | VISTA/VSIR siRNA Set For knockdown verification. Sequence-verified targeting. |
View VISTA/VSIR Products |
| Related Target: PSGL-1 | PSGL-1 (SELPLG) Primary interacting partner/ligand in acidic tumor microenvironment. |
View PSGL-1 Products |
| Related Target: PD-L1 | PD-L1 (CD274) Complementary checkpoint pathway; dual targeting rationale. |
View PD-L1 Products |
| Related Target: VSIG-3 | VSIG-3 (ILDR1) Putative ligand for VISTA; receptor-ligand interaction studies. |
View VSIG-3 Products |
| Related Target: PD-1 | PD-1 (PDCD1) Synergistic checkpoint target for combination therapy. |
View PD-1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| pH-Dependent Binding (TME specific) | Native glycosylation (HEK293 expressed) ensuring structural integrity across pH gradients. |
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno VISTA ortholog proteins available with >95% purity; Sequence Verified. |
| Epitope specificity vs. homologs | IgV-domain strict verification by mass spec; Low endotoxin for sensitive immune cell assays. |
| Cell-based checkpoint assays | Lentivirus for stable Jurkat reporter lines; Native conformation preservation. |
| Internalization analysis (ADC potential) | High-purity ECD-Fc with validated Fc-tag for FACS-based uptake assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for specificity checks in cell-based assays. |
Live VISTA/VSIR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
VISTA (V-domain Ig suppressor of T cell activation) represents a critical negative checkpoint regulator distinct from the PD-1/PD-L1 axis. Predominantly expressed on myeloid-derived suppressor cells (MDSCs) and neutrophils, VISTA offers a novel mechanism to overcome immunotherapy resistance in "cold" tumor microenvironments.
The race for VISTA/VSIR therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecifics and combination regimens. As first-generation therapies reach the clinic, the next wave of R&D is targeting the acidic tumor microenvironment (pH-selective activation) and bypassing resistance mechanisms developed against PD-1/L1 blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Kineta, Sensei Biotherapeutics, Janssen, Merck, ImmuNext | Solid Tumors (Prostate, NSCLC, Melanoma) | pH-dependent binding SPR (Need native-folded ECD-Fc); Cross-reactivity panel. |
| Bispecific | Symphony Biosciences, Agenus (AGEN1777), Curis | Immunotherapy combos, Solid Tumors, Hematologic Malignancies | Heterodimer Validation; Dual-target bridging assay (Need PD-L1 + VISTA proteins). |
| Small Molecule | Curis/Immutep (CA-170) | Refractory Cancers, NSCLC, Head & Neck Cancer | Competitive binding assay (Need VISTA ECD protein); SPR validation; Selectivity Assay (Need structural integrity at varying pH). |
| ADC | Preclinical | Myeloid-enriched Tumors | Internalization Assay (Need high-purity ECD-Fc); Lysosomal trafficking confirmation. |